An interim analysis of all available data, including patients who have completed 36 weeks of treatment, will be triggered when approximately 100 patients reach 24 weeks of treatment. Based on updated near- term enrolment projections, this is anticipated in Q4 2025.
Ann: Actinogen March 2025 quarterly activity report & Appendix 4C, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.54M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 1.9¢ | $15.65K | 783.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 868881 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 1785641 | 6 |
View Market Depth
| Last trade - 15.57pm 17/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |